Is grey literature essential for a better control of publication bias in psychiatry? An example from three meta-analyses of schizophrenia

European Psychiatry

Volumn 20, Issue 8, 2005, Pages 550-553

  Martin, José Luis R ^a   Pérez, Víctor ^b   Sacristán, Montse ^a   Álvarez, Enric ^b  

^a Castile La Mancha Health Research Foundation FISCAM   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Grey literature; Publication bias; Schizophrenia; Systematic reviews

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

CLINICAL TRIAL; HUMAN; MEDICAL LITERATURE; META ANALYSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; PUBLICATION; PUBLISHING; QUALITY CONTROL; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 28744449805     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2005.03.011     Document Type: Article

References (18)

1. M. Clarke, and A.D. Oxman Cochrane Reviewers' Handbook 4.2.0 The Cochrane Library, Issue 2 2003 Update Software. Update quarterly Oxford [updated March 2003]
2. D.J. Cook, G.H. Guyatt, and G. Ryan Should unpublished data be included in meta-analysis? J. Am. Med. Assoc. 269 1993 2749 2753
3. Current Controlled Trials. MetaRegister of controlled clinical trials. http://www.controlled-trials.com.
4. K. Dickersin, and D. Rennie Registering clinical trials J. Am. Med. Assoc. 290 2003 516 523
5. L. Duggan, M. Fenton, R.M. Dardennes, A. El-Dosoky, and S. Indran Olanzapine for schizophrenia (Cochrane Review) The Cochrane Library, Issue 1 2004 Update Software Oxford
6. M. Egger Meta-analysis bias in location and selection of studies Br. Med. J. 316 1998 61 66
7. M. Egger, P. Jüni, C. Bartlett, F. Holenstein, and J. Sterne How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study Health Technol. Assess 7 1 2003 1 76
8. S. Heres, S. Wagenpfeil, J. Hamann, W. Kissling, and S. Leucht Language bias in neuroscience- Is the tower of Babel located in Germany? Eur. Psychiatry 19 2004 230 232
9. S. Hopewell, S. McDonald, M. Clarke, and M. Egger Grey literature in meta-analysis of randomized trials of health care interventions (Cochrane Methodology Review) The Cochrane Library, Issue 1 2003 Update Software Oxford
10. R.H. Hunter, C.B. Joy, E. Kennedy, S.M. Gilbody, and F. Song Risperidone versus typical antipsychotic medication for schizophrenia (Cochrane Review) The Cochrane Library, Issue 1 2004 Update Software Oxford
11. M. Jakovljevic, and M.R.K. Dossenbach Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia Psychiatric Danubina 11 1999 3 10
12. P. Jüni, D.G. Altman, and M. Egger Assessing the quality of controlled clinical trials Br. Med. J. 323 2001 42 46
13. D. Moher, D.J. Cook, S. Eastwood, I. Olkin, D. Rennie, and D.F. Stroup Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement Lancet 354 1999 1896 1900
14. D. Moher, K.F. Schulz, and D.G. Altman for the CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials Lancet 357 2001 1191 1194
15. C.D. Mulrow Systematic reviews: rationale for systematic reviews Br. Med. J. 309 1994 597 599
16. K.F. Schulz Randomised trials, human nature, and reporting guidelines Lancet 348 1996 596 598
17. K.F. Schulz, I. Chalmers, R.J. Hayes, and D.G. Altman Dimensions of methodological quality associated with estimates of treatment effects in controlled trials J. Am. Med. Assoc. 273 1995 408 412
18. M. Srisurapanont, C. Disayavanish, and K. Taimkaew Quetiapine for schizophrenia (Cochrane Review) The Cochrane Library, Issue 1 2004 Update Software Oxford